- Penumbra has been impacted by the pandemic and the recall of its leading-edge neurovascular aspiration catheter, but those only look like bumps in the growth story.
- With the JET 7 Flex Xtra off the market, management is seeing robust demand for older models and is currently capacity-constrained; a new neuro catheter may appear in 2021.
- Peripheral thrombectomy remains a very strong growth opportunity for Penumbra.
- Penumbra remains a premier med-tech growth story, but at over 12x '22 revenue, the valuation is not low.
For further details see:
A Recall-Driven Slowdown Only A Minor Setback For Penumbra